FDA Brief

Warning letters Drugs

FDA warning letter to

McConnell Labs Inc.

High riskIssued Oct 18, 2022Posted Nov 1, 2022Division of Pharmaceutical Quality Operations IV

McConnell Labs Inc. released hand sanitizers without raw material identity, finished product, or stability testing, FDA says.

What happened

FDA reviewed records McConnell Labs submitted in response to a July 30, 2021 request for records under section 704(a)(4). The records showed no identity testing of incoming raw materials such as ethanol and isopropyl alcohol, no methanol testing, no finished-product identity or strength testing before release, and unsupported expiration dates for hand sanitizers.

What FDA found

  1. The company did not test incoming raw materials, including ethanol and isopropyl alcohol, to confirm their identity and did not test them for methanol.

    21 CFR 211.84(d)(1)
  2. Hand sanitizer batches were only checked for weight, density, color, viscosity, and smell, not identity or strength of the active ingredient, before release.

    21 CFR 211.165(a)
  3. The company assigned unsupported expiration periods to hand sanitizers, including “36 months after opening” and “10 years past the manufacturing date,” without stability data.

    21 CFR 211.166(a)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, including an independent review of its material system, full testing of distributed batches, stability data, and use of a qualified CGMP consultant.

Who should pay attention

  • brands that buy hand sanitizer from this contract manufacturer
  • distributors and retailers selling Light Elegance Hand Sanitizer
  • quality teams at OTC drug manufacturers using supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk